2025 Novel Drug Approvals
Transformative Medicine · 30.03.2026 · 5 (1) · 17
DOI: 10.54299/tmed/cram4550 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transformative Medicine, online erschienen am 30.03.2026. Verfasst von Katherine Ghattas und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The year 2025 marked another strong chapter in pharmaceutical innovation, with multiple novel therapies gaining approval from the U.S. Food and Drug Administration (FDA). These approvals reflect continued progress in addressing unmet medical needs across a wide range of disease states. This article reviews the FDA’s 2025 novel drug approvals, spotlighting a few therapeutic advancements and emerging trends. A comprehensive table of all approved agents is provided, along with a focused discussion of four particularly impactful therapies: donidalorsen (Dawnzera), taletrectinib (Ibtrozi), delgocitinib (Anzupgo), gepotidacin (Blujepa), etripamil (Cardamyst). Each of these agents represents a step forward in its respective field and shows the evolving landscape of modern therapeutics.
Zitieren
APA
Ghattas, K., & Rawa, A. (2026). 2025 Novel Drug Approvals. Transformative Medicine, 5(1), 17. https://doi.org/10.54299/tmed/cram4550
Vancouver
Ghattas K, Rawa A. 2025 Novel Drug Approvals. Transformative Medicine. 2026;5(1):17. doi:10.54299/tmed/cram4550
BibTeX
@article{Ghattas2026,
author = {Ghattas, Katherine and Rawa, Amanda},
title = {2025 Novel Drug Approvals},
journal = {Transformative Medicine},
year = {2026},
volume = {5},
number = {1},
pages = {17},
doi = {10.54299/tmed/cram4550}
}
EUVIMED